Breaking News
Investing Pro 0
Extended Sale! Save on premium data with Claim 60% OFF

OKYO Pharma eyes progress for OK-101 in 2023, releases interim results

Published Dec 30, 2022 09:34 Updated Dec 30, 2022 10:10
Saved. See Saved Items.
This article has already been saved in your Saved Items
 
© Reuters. OKYO Pharma eyes progress for OK-101 in 2023, releases interim results
 
OKYO
0.00%
Add to/Remove from a Portfolio
Add to Watchlist
Add Position

Position added successfully to:

Please name your holdings portfolio
 

Proactive Investors - OKYO Pharma Ltd (LON:OKYO) has released its interim results for the six months ended 30 September 2022, a period in which its primary focus was on the development of its Dry Eye Disease (DED) drug, OK-101.

The biopharmaceutical company, in a statement, highlighted that during the six-month reporting period it completed various stages of development for OK-101 - including the formulation of the drug and initial stability studies, the development of bioanalytical methods to support the clinical program, and the manufacture of cGMP OK-101 for clinical trials.

It also completed toxicokinetic method development, and toxicology studies in rabbits and dogs during the period.

Since the period’s end, in November, OKYO announced it had made an investigational new drug (IND) filing with the US Food & Drug Administration (FDA) for OK-101 to treat DED.

The IND was subsequently cleared in December 2022, allowing the company to proceed with a Phase 2 trial in DED patients, which it expects to initiate in the first quarter of 2023.

The Phase 2 trial is expected to be completed within 6-9 months of enrolling the first patient.

Along with the work on OK-101, OKYO has also been developing OK-201 as a potential non-opioid analgesic for the treatment of neuropathic corneal pain.

However, amidst the success of OK-101 to date, the company has opted to prioritise its efforts on OK-101 and pause further development of OK-201.

In terms of financials, the pre-revenue drug development company reported a loss of £4.6mln. It ended September with total assets of £1.6mln, with cash on hand reported at £0.6mln.

Read more on Proactive Investors UK

Disclaimer

OKYO Pharma eyes progress for OK-101 in 2023, releases interim results
 

Related Articles

Add a Comment

Comment Guidelines

We encourage you to use comments to engage with users, share your perspective and ask questions of authors and each other. However, in order to maintain the high level of discourse we’ve all come to value and expect, please keep the following criteria in mind: 

  • Enrich the conversation
  • Stay focused and on track. Only post material that’s relevant to the topic being discussed.
  • Be respectful. Even negative opinions can be framed positively and diplomatically.
  •  Use standard writing style. Include punctuation and upper and lower cases.
  • NOTE: Spam and/or promotional messages and links within a comment will be removed
  • Avoid profanity, slander or personal attacks directed at an author or another user.
  • Don’t Monopolize the Conversation. We appreciate passion and conviction, but we also believe strongly in giving everyone a chance to air their thoughts. Therefore, in addition to civil interaction, we expect commenters to offer their opinions succinctly and thoughtfully, but not so repeatedly that others are annoyed or offended. If we receive complaints about individuals who take over a thread or forum, we reserve the right to ban them from the site, without recourse.
  • Only English comments will be allowed.

Perpetrators of spam or abuse will be deleted from the site and prohibited from future registration at Investing.com’s discretion.

Write your thoughts here
 
Are you sure you want to delete this chart?
 
Post
Post also to:
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Thanks for your comment. Please note that all comments are pending until approved by our moderators. It may therefore take some time before it appears on our website.
 
Are you sure you want to delete this chart?
 
Post
 
Replace the attached chart with a new chart ?
1000
Your ability to comment is currently suspended due to negative user reports. Your status will be reviewed by our moderators.
Please wait a minute before you try to comment again.
Add Chart to Comment
Confirm Block

Are you sure you want to block %USER_NAME%?

By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.

%USER_NAME% was successfully added to your Block List

Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.

Report this comment

I feel that this comment is:

Comment flagged

Thank You!

Your report has been sent to our moderators for review
Continue with Google
or
Sign up with Email